Detailed notes on Pulmonary artery hypertension in systemic sclerosis: Screening, diagnosis and recent trends in treatment. From rheumatology textbooks and major journals
Reading File
Finding Sources
Finding Sources
Searching PubMed
"pulmonary arterial hypertension" AND "systemic sclerosis" AND screening
Searching the Web
pulmonary arterial hypertension systemic sclerosis screening diagnosis treatment 2024 2025 guidelines
Finding Sources
Finding Sources
Reading Article
Reading Article
Reading Web Page
SSc-PAH screening diagnosis treatment algorithm
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching PubMed
"systemic sclerosis" AND "pulmonary arterial hypertension" AND sotatercept
Reading File
Reading File
Reading Article
Reading Article
Finding Sources
Finding Sources
Reading Article
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I now have comprehensive data from multiple major textbooks and recent journals to compile detailed notes. Let me write the full structured notes.
Pulmonary Arterial Hypertension in Systemic Sclerosis: Detailed Clinical Notes
Sources: Firestein & Kelley's Textbook of Rheumatology (2022), Rheumatology 2-Vol Set (Elsevier, 2022), Goldman-Cecil Medicine (2022), Murray & Nadel's Textbook of Respiratory Medicine, Braunwald's Heart Disease (15th ed.), Fishman's Pulmonary Diseases; supplemented with recent literature (2024-2026).
1. Epidemiology and Clinical Significance
SSc-PAH is one of the most common and most clinically important manifestations of systemic sclerosis. PAH occurs in 7-15% of SSc patients and is a leading cause of disease-related death, accounting for approximately 20-30% of SSc mortality. It most commonly complicates limited cutaneous SSc (lcSSc/CREST), although diffuse cutaneous SSc patients with nucleolar ANA patterns (anti-U3-RNP, anti-Th/To) are also at substantial risk.
Compared to idiopathic PAH (iPAH), SSc-PAH carries a significantly worse prognosis: 3-year survival in contemporary rheumatology-based registry data (PHAROS study) reaches 75%, which is poorer than iPAH at similar time points. This reflects more aggressive vascular remodeling, co-existing cardiac fibrosis, impaired RV-PA coupling, and poor responses to conventional vasodilator therapies.
- Fishman's Pulmonary Diseases: "PAH (WHO Group 1) occurs in approximately 10% of cases of systemic sclerosis and is primarily seen in the limited cutaneous form (CREST syndrome)."
- Goldman-Cecil Medicine, p. 814: "The prevalence of pulmonary arterial hypertension [in SSc] is in the range of 7 to 12%."
2. Pathophysiology
2a. Vascular Pathology
SSc-PAH involves progressive obliteration of the pulmonary microvasculature through:
- Obliterative intimal lesions with matrix accumulation (see histology below)
- Smooth muscle hyperplasia and medial thickening
- Adventitial expansion
- Endothelial dysfunction with reduced nitric oxide (NO) and prostacyclin production, and increased endothelin-1 (ET-1) secretion
Histology: Pulmonary artery changes in SSc-PAH. Elastin stain showing intimal thickening with matrix accumulation on the luminal side of the elastic lamina. Note only mild interstitial fibrosis - Rheumatology 2-Vol (Elsevier, 2022)
Key distinctions from iPAH:
- Pulmonary veno-occlusive disease (PVOD) is rare in iPAH but common in SSc-PAH, contributing to poor response to vasodilators
- Plexogenic lesions are rare in SSc-PAH (unlike iPAH)
- Pulmonary thrombosis is more prevalent in SSc-PAH
- Patients with SSc-PAH show impaired RV-PA coupling at much lower RV afterload levels than iPAH, linked to increased interstitial RV cardiac fibrosis
- Rheumatology 2022 (Elsevier), p. 6565: "Pulmonary venoocclusive disease, which is rare in idiopathic PAH, occurs frequently in SSc-PAH, along with evidence of pulmonary thrombosis."
2b. Immune and Molecular Mechanisms
The pathogenesis involves:
- Immune dysregulation: T-cell activation, B-cell dysregulation, autoantibody production
- Chronic inflammation: IL-6, IL-8, VEGF, TGF-β overexpression
- Activin/TGF-β pathway dysregulation: now a recognized therapeutic target
- BMPR2 pathway impairment (as in iPAH), contributing to impaired vascular repair
- Endothelin-1 excess: a potent vasoconstrictor and proliferative mediator - the basis for ERA therapy
Recent evidence (Birnhuber A et al., Curr Opin Pulm Med 2026 [PMID: 42267527]) highlights preclinical advances in understanding SSc-specific vascular-immune interactions and their therapeutic implications.
3. Screening
3a. Who to Screen
All SSc patients should undergo annual screening for PAH, regardless of cutaneous subtype or symptom status. Current guidelines recommend formal screening using objective testing. High-risk features that should heighten vigilance:
| Risk Factor | Significance |
|---|---|
| Longer disease duration (>3 years) | Increased cumulative risk |
| Older age | Independent predictor |
| Severe Raynaud's/digital ulcers | Reflects vasculopathy severity |
| Multiple/large telangiectasias | Marker of vascular disease extent |
| Isolated DLCO decline | Surrogate of pulmonary vascular disease |
| FVC%/DLCO% ratio >1.6 | Suggests vascular >parenchymal disease |
| NT-proBNP elevation (>395 pg/mL) | Right heart strain |
| Anti-centromere antibody | Strongly associated with lcSSc-PAH |
| Anti-U1-RNP, U3-RNP, Th/To antibodies | Additional PAH risk markers |
| Anti-Ro52 antibodies | Emerging risk marker |
Firestein & Kelley's Textbook of Rheumatology, p. 1859 (Fig. 85.12 source)
3b. Screening Tests
1. Pulmonary Function Tests (PFTs)
- DLCO is typically significantly reduced, often to <40-60% predicted, frequently years before PAH becomes manifest
- The FVC%/DLCO% ratio >1.6 is a strong clue to pulmonary vascular disease (as opposed to ILD, where both FVC and DLCO fall)
- An isolated low DLCO without significant restriction or obstruction should trigger further evaluation
- Rheumatology 2022 (Elsevier): "The diffusing capacity for carbon monoxide (DLCO) almost always is significantly decreased long before PAH develops, often as low as 40%."
2. Echocardiography (ECHO)
- First-line noninvasive screening tool; recommended annually in all SSc patients
- The 2022 ESC/ERS guidelines updated the echocardiographic threshold: TRV >2.8 m/s (previously 2.9 m/s) is now the cut-off for intermediate-high probability of PH, especially combined with other echocardiographic signs
- RVSP >45 mmHg predicts PAH by RHC with ~95% accuracy
- Additional echo signs of PH: RV/LV basal diameter ratio ≥1.0, interventricular septal flattening, TAPSE/sPAP ratio <0.55 mm/mmHg, PA diameter >25 mm, RVOT acceleration time <105 ms
- Echo alone carries important false-positive and false-negative rates in SSc, necessitating RHC for confirmation
3. Biomarkers
- NT-proBNP: even modest elevations >395 pg/mL indicate right heart strain and should trigger evaluation
- BNP: used alongside NT-proBNP for risk stratification
- FVC%/DLCO% ratio: composite PFT biomarker
- Autoantibodies: anti-centromere, U1-RNP, U3-RNP, Th/To, Ro52 as risk stratification tools
4. ECG
- Can be normal early; as disease progresses shows RV hypertrophy, right axis deviation, right heart strain pattern
3c. The DETECT Algorithm
The DETECT algorithm is the most evidence-based, validated screening tool for SSc-PAH, specifically designed for SSc patients at increased risk. It follows a two-step approach:
Eligibility criteria: SSc patients with:
- Disease duration >3 years
- DLCO <60% predicted
- FVC ≥40% predicted (excludes severe ILD)
Step 1 - Combines 6 clinical/lab variables to generate a risk score:
- FVC%/DLCO% ratio
- NT-proBNP
- Serum urate
- Any telangiectasias
- Anti-centromere antibody
- Right axis deviation on ECG → If score exceeds threshold: proceed to echocardiography
Step 2 - ECHO variables:
- TRV (tricuspid regurgitation velocity)
- Right atrial area → If combined score exceeds threshold: refer for RHC
The original DETECT study (Coghlan et al., Ann Rheum Dis 2014; 488 patients, 31% had PH on RHC, 19% had PAH) demonstrated only 4% missed PAH diagnoses with this algorithm.
- Murray & Nadel's Respiratory Medicine: "These analyses identified eight clinical variables that, when applied in a two-step algorithm, predicted the presence of PH on RHC with a low rate (4%) of missed PAH diagnoses."
- Firestein & Kelley's: "DETECT has been validated across many general scleroderma cohorts exhibiting a consistently high sensitivity and negative predictive value, but modest specificity and positive predictive value."
Limitations: High false-positive rate may lead to unnecessary RHC referrals. The DETECT algorithm will also increase identification of "borderline PAH" (mPAP 21-24 mmHg) for which approved therapies are lacking.
2025 Consensus Update (Sari et al., Anatol J Cardiol 2025 [PMID: 41085415], multidisciplinary group of 10 rheumatologists, 4 cardiologists, 3 pulmonologists): Recommends prioritizing echocardiography-based screening for SSc patients and those with CTD overlap features of SSc. Insufficient data to recommend routine screening in asymptomatic non-SSc CTD patients without SSc overlap.
3d. ASIG (Australian Scleroderma Interest Group) Algorithm
The ASIG algorithm is an alternative two-step tool using a different set of variables. It performs comparably to DETECT in external validation cohorts. The choice between DETECT and ASIG depends on institutional preference and resource availability.
4. Diagnosis
4a. Hemodynamic Definition
The 2022 ESC/ERS guidelines updated PAH definitions:
- Mean pulmonary arterial pressure (mPAP) ≥20 mmHg (lowered from >25 mmHg)
- Pulmonary capillary wedge pressure (PCWP) ≤15 mmHg
- Pulmonary vascular resistance (PVR) >2 Wood Units (lowered from ≥3 WU)
All three criteria must be met on right heart catheterization (RHC) - the gold standard for PAH diagnosis.
- Firestein & Kelley's, p. 1859: "It is now defined as resting mean pulmonary arterial pressure equal to or greater than 20 mm Hg, with normal pulmonary capillary wedge pressure equal to or less than 15 mm Hg and pulmonary vascular resistance >3 wood units, although this threshold has been recently lowered to >2 wood units in the 2022 ESC/ERS guidelines."
4b. Right Heart Catheterization (RHC)
RHC is mandatory for diagnosis. Indications for RHC referral in SSc:
- eRVSP >45 mmHg on ECHO
- Unexplained dyspnea with eRVSP 35-45 mmHg + additional echo signs
- DETECT/ASIG algorithm threshold reached
- Low DLCO + normal FVC + elevated BNP/NT-proBNP, even with normal ECHO
- Dyspnea without ILD and progressive DLCO decline
RHC provides:
- Direct measurement of mPAP, PCWP, cardiac output, PVR
- Differentiation of PAH from left heart disease (group 2 PH) - especially important in SSc where diastolic dysfunction and PVOD co-exist
- Vasodilator challenge (acute vasoreactivity testing) - though acute response is rare in SSc-PAH and calcium-channel blocker therapy is generally not appropriate
4c. Distinguishing PH Types in SSc
SSc patients can develop multiple PH phenotypes simultaneously or sequentially:
- Group 1 PAH (pure pulmonary vascular disease) - most common in lcSSc
- Group 2 PH (left heart disease) - diastolic dysfunction, elevated PCWP
- Group 3 PH (ILD-associated) - must have significant ILD + mPAP >35 mmHg or PVR >5 WU
- PVOD phenotype - SSc-specific, poor prognosis, risk of pulmonary edema with vasodilators
This distinction critically affects treatment. Vasodilators may worsen group 2 PH or PVOD.
4d. Additional Diagnostic Investigations
- HRCT chest: assess for ILD (NSIP pattern most common in SSc), exclude significant fibrosis driving group 3 PH; also can show PA enlargement
- V/Q scan: exclude chronic thromboembolic PH (group 4) - important to rule out in all patients
- 6-minute walk test (6MWT): baseline functional assessment; poor correlation with hemodynamic severity in SSc compared to iPAH
- Cardiopulmonary exercise testing (CPET): may improve diagnostic accuracy, especially for "exercise-induced PH" (mPAP >30 mmHg on exercise RHC); role not yet standardized
- Cardiac MRI: identifies subclinical RV dysfunction and myocardial fibrosis
- Nailfold capillaroscopy: "late" SSc pattern (avascular areas, giant capillaries) correlates with end-organ vascular disease including PAH (Ickinger et al., Best Pract Res Clin Rheumatol 2026 [PMID: 41826085])
5. Clinical Approach (Flowchart)
Fig. 85.12 from Firestein & Kelley's Textbook of Rheumatology: Approach to scleroderma-associated PAH. Left panel shows risk factors; center shows annual assessment pathway; right panel shows treatment by WHO functional class. 6MWD = 6-minute walk distance; ERA = endothelin receptor antagonist; PDE5i = phosphodiesterase-5 inhibitor; PRA = prostacyclin IP receptor agonist.
6. Risk Stratification at Diagnosis and Follow-Up
The 2022 ESC/ERS guidelines and the 7th WSPH (2024) recommend a 4-strata risk stratification at diagnosis and every 3-6 months:
- Low risk: FC I-II, 6MWD >440 m, NT-proBNP <300 ng/L, low/normal RV function, mPAP <35-40 mmHg, PVR <5 WU
- Intermediate-low risk
- Intermediate-high risk
- High risk: FC IV, 6MWD <165 m, NT-proBNP >1400 ng/L, pericardial effusion, CI <2.0 L/min/m², RA area >26 cm²
SSc-PAH patients tend to present at higher risk categories than iPAH, partly due to diagnostic delay.
Risk stratification guides treatment escalation:
- If not achieving low-risk at 3-6 months: escalate therapy
- High-risk category: consider listing for lung transplant
7. Treatment
7a. General Principles
Treatment of SSc-PAH follows general PAH management guidelines, but SSc patients respond less well to vasodilator-based therapies compared to iPAH patients. This reflects the underlying vasculopathy combined with fibrosis, PVOD, and RV myocardial disease. The multidisciplinary approach is especially important in SSc, combining PH specialist input with rheumatology.
- Rheumatology 2022 (Elsevier): "Scleroderma patients do not respond as well to these many treatments compared to those with idiopathic PAH. Thus in scleroderma, once the diagnosis of PAH is confirmed by RHC, treatment with at least one drug should be instituted."
Acute vasoreactivity testing is rarely positive in SSc-PAH; calcium-channel blockers are generally contraindicated.
7b. Conventional Vasodilator Therapies
Three main pharmacological pathways are targeted:
Endothelin Receptor Antagonists (ERAs)
| Drug | Selectivity | Route | Dosing | Key Adverse Effects |
|---|---|---|---|---|
| Bosentan | Non-selective (ETA+ETB) | Oral | 62.5 mg BD x 4 wks, then 125 mg BD | LFT elevation (10%), teratogenic, fluid retention, reduces oral anticoagulant effect |
| Ambrisentan | ETA-selective | Oral | 5-10 mg OD | Teratogenic, fluid retention, peripheral edema |
| Macitentan | Non-selective (tissue-specific) | Oral | 10 mg OD | Teratogenic, fluid retention, anemia |
All approved for SSc-PAH based on RCT data.
PDE-5 Inhibitors (Nitric Oxide Pathway)
| Drug | Route | Dosing | Comments |
|---|---|---|---|
| Sildenafil | Oral | 20 mg TDS | Well tolerated; headache, visual disturbance |
| Tadalafil | Oral | 40 mg OD | Longer duration of action |
Soluble Guanylate Cyclase (sGC) Stimulator
| Drug | Route | Comments |
|---|---|---|
| Riociguat | Oral 2.5 mg BD | Cannot be used with PDE5i; reserved for severe disease or PDE5i failure |
Prostacyclin Pathway
| Drug | Route | Dosing | Comments |
|---|---|---|---|
| Epoprostenol (prostacyclin) | Continuous IV | Titrated | Gold-standard for FC IV; only prostacyclin with RCT specifically in SSc-PAH showing improved 6MWD, functional class, hemodynamics |
| Treprostinil | SC/IV/inhaled/oral | Titrated | SC site pain; less abrupt deterioration than epoprostenol if interrupted |
| Iloprost | Inhaled | 6-9x daily | Licensed for PAH |
| Selexipag (IP receptor agonist) | Oral | BD | GRIPHON trial included CTD-PAH; recently approved |
"One high-quality RCT in patients with SSc indicates that continuous intravenous epoprostenol improves exercise capacity, functional class, and haemodynamic measures in SSc-PAH. Intravenous epoprostenol should be considered for the treatment of patients with severe SSc-PAH (class III and IV)." - Rheumatology 2022 (Elsevier)
7c. Combination Therapy - Key Trials
AMBITION Trial (Ambrisentan + Tadalafil):
- Initial combination vs. monotherapy in treatment-naive PAH
- Sub-analysis of CTD-PAH/SSc-PAH patients:
- Risk of clinical failure 52% lower with combination vs. monotherapy in CTD-PAH (HR 0.483)
- 54% lower in SSc-PAH specifically (HR 0.463)
- Combination ambrisentan + tadalafil is now the preferred initial strategy for most SSc-PAH patients
- Rheumatology 2022 (Elsevier), p. 2964
Current recommendation: Most SSc-PAH patients with FC II-III should be initiated on upfront combination ERA + PDE5i rather than sequential monotherapy.
EDITA Study (Early Treatment in Borderline PAH):
- Ambrisentan in SSc patients with mildly elevated mPAP (21-24 mmHg) - to assess benefit of early intervention in "borderline" PAH
- Important in context of lowered diagnostic threshold
- Rheumatology 2022 (Elsevier), p. 2979
Bosentan in SSc-PAH (2024 Meta-Analysis):
- Bearzi P et al., Clin Exp Rheumatol 2024 [PMID: 38819960]: Bosentan reduces echocardiographic systolic PAP in SSc-related PH
7d. Sotatercept - Major Recent Advance
Sotatercept is a fusion protein acting as an activin signaling inhibitor (targeting the TGF-β/activin/BMPR2 pathway), approved in 2024 by the FDA for PAH.
- Mechanism: Sequesters activin ligands (particularly activin A) that drive vascular smooth muscle proliferation and remodeling
- STELLAR trial: Demonstrated significant improvement in 6MWD, hemodynamics, and clinical worsening in patients already on background dual/triple PAH therapy
- ZENITH trial (Humbert M et al., NEJM 2025): Sotatercept in high-risk PAH patients showed markedly improved outcomes [PMID referenced in Villa et al. 2026]
- SSc-PAH patients were included in these trials; the activin pathway is particularly relevant given the pro-fibrotic milieu in SSc
- SSc-PAH-specific data are emerging (NCT06865118 observational protocol 2025)
- Current 2024 7th WSPH treatment algorithm incorporates sotatercept as an add-on therapy for patients not at low risk despite dual therapy
"Novel therapeutic targets such as the activin/TGF-β pathway have been incorporated into updated treatment algorithms. Although CTD-PAH remains associated with worse outcomes than idiopathic PAH, recent advances in screening, risk assessment, and targeted therapies have begun to improve the trajectory of the disease." - CTD-PAH practical review 2025 (PMC12536151)
Villa A et al. (Eur Respir Rev 2026, PMID: 41708122): A 2026 systematic review specifically on SSc-PAH management identified critical gaps: lack of SSc-focused trials, heterogeneity in hemodynamic severity, and exclusion of key comorbidities (ILD) from trials.
7e. Immunosuppressive Therapy in SSc-PAH
Unlike SLE-associated PAH (which can respond dramatically to immunosuppression), SSc-PAH has a predominantly fibrotic/obliterative vasculopathy and shows limited responsiveness to immunosuppressants. However:
- Cyclophosphamide, mycophenolate mofetil: Limited role; may benefit inflammatory phenotypes or overlap CTD-PAH
- Rituximab (anti-CD20): Emerging evidence; Touil A et al. systematic review (Expert Rev Respir Med 2026, PMID: 40905396): RTX appeared effective and safe in CTD-PH including SSc cases; primarily prospective data from Russia and USA; improvement in clinical/paraclinical parameters; limited to 6 studies
- IL-6 receptor inhibitors (tocilizumab): Under investigation given IL-6's role in vascular remodeling in SSc
- Glucocorticoids: Low-dose may have a role in inflammatory phenotypes but high-dose steroids risk SSc renal crisis
Yokoyama et al. (Biomolecules 2026, PMID: 41594679): "Immune-targeted therapies such as glucocorticoids, cyclophosphamide, mycophenolate mofetil, rituximab, and IL-6 receptor inhibitors may benefit inflammation-dominant PAH phenotypes, while fibrotic phenotypes continue to demonstrate limited responsiveness."
7f. 7th WSPH 2024 Treatment Algorithm
The 2024 7th World Symposium on Pulmonary Hypertension recommended:
- Initial risk stratification (4-strata model)
- Low/intermediate-low risk (FC I-II): Upfront dual therapy (ERA + PDE5i; ambrisentan + tadalafil preferred)
- Intermediate-high/high risk (FC III-IV): Upfront dual or triple therapy; consider adding prostacyclin pathway agent early; IV epoprostenol for FC IV
- Re-assess at 3-6 months: If not achieving low risk, escalate
- Sotatercept: Add-on for patients not at low risk on background oral therapy (per STELLAR/ZENITH data)
- Lung transplant referral: Failed maximal medical therapy
For SSc-PAH specifically, given the known poor response:
- Lower threshold for early combination therapy
- Lower threshold for escalation
- Comorbidities (ILD, cardiac fibrosis, GI disease) must be actively managed alongside PAH therapy
- Avoid acute vasoreactivity testing with calcium-channel blockers
7g. Surgical/Interventional Options
- Balloon pulmonary angioplasty (BPA): For CTEPH (Group 4); not indicated in SSc-PAH group 1
- Atrial septostomy: Rarely used; may provide palliative benefit in refractory high-risk PAH
- Lung transplant: Considered when PAH therapy fails; outcomes in SSc are complicated by extrapulmonary SSc disease (esophageal dysmotility, bowel disease, systemic fibrosis); careful patient selection required
8. Prognosis and Follow-Up Monitoring
Prognostic factors in SSc-PAH (worse than iPAH):
- Older age at diagnosis
- Worse baseline hemodynamics (lower CI, higher PVR)
- Lower 6MWD
- Elevated NT-proBNP
- FC III/IV at diagnosis
- RV dysfunction (TAPSE, tricuspid annular plane systolic excursion)
- Impaired RV-PA coupling (TAPSE/sPAP ratio)
- Co-existing ILD
Follow-up monitoring (every 3-6 months):
- ECHO + TRV, TAPSE, RA area, RV/LV ratio
- 6-minute walk test
- NT-proBNP/BNP
- WHO functional class
- Blood tests: FBC, LFTs (for bosentan), renal function
- Repeat RHC if clinical deterioration or escalation decision needed
- Annual PFT
9. Summary of Key Points
| Topic | Key Points |
|---|---|
| Prevalence | 7-15% of all SSc; leading cause of SSc mortality |
| Subset | Mainly lcSSc; also diffuse SSc with nucleolar ANA |
| Prognosis | Worse than iPAH; 3-year survival ~75% (PHAROS) |
| Pathology | Obliterative intimal lesions, PVOD, no plexiform lesions |
| Screening tool | DETECT algorithm (2-step), annual ECHO, PFTs, biomarkers |
| Diagnosis | RHC: mPAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 WU (2022 ESC/ERS) |
| Vasoreactivity | Rarely positive; CCBs generally not used |
| Initial treatment | Upfront combination ERA + PDE5i (ambrisentan + tadalafil; AMBITION data) |
| Severe disease | IV epoprostenol + combination oral therapy |
| New agent | Sotatercept (activin inhibitor, 2024 FDA-approved) - add-on therapy |
| Immunosuppression | Limited role in SSc-PAH; rituximab emerging (CTD-PAH reviews) |
| Transplant | Considered in refractory cases; careful patient selection |
Key References
Textbooks:
- Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set (2022), Chapter 85
- Rheumatology, 2-Volume Set (Elsevier, 2022), Chapter 150/152
- Goldman-Cecil Medicine, International Edition (2022), Chapter 69
- Murray & Nadel's Textbook of Respiratory Medicine (6th ed.), Chapter 83/84
- Braunwald's Heart Disease (15th ed.), Chapter 13
Key Recent Literature:
- Villa A et al. "Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons." Eur Respir Rev 2026. [PMID: 41708122] - Systematic review identifying SSc-PAH management gaps
- Sari A et al. "Screening for Pulmonary Hypertension in Connective Tissue Diseases: Literature Review and Multidisciplinary Consensus Statement." Anatol J Cardiol 2025. [PMID: 41085415]
- Cullivan S et al. "Pulmonary Hypertension in Systemic Sclerosis." Semin Respir Crit Care Med 2024. [PMID: 38531379]
- Yokoyama Y et al. "Connective Tissue Disease-Associated PAH: Current Therapeutic Strategies and Future Prospects." Biomolecules 2026. [PMID: 41594679]
- Touil A et al. "Rituximab treatment for CTD-associated pulmonary hypertension." Expert Rev Respir Med 2026. [PMID: 40905396]
- Bearzi P et al. "Bosentan effect on echocardiographic systolic PAP in SSc-related PH." Clin Exp Rheumatol 2024. [PMID: 38819960]
- Coghlan JG et al. "Evidence-based detection of PAH in systemic sclerosis: the DETECT study." Ann Rheum Dis 2014;73:1340-1349. (Foundation screening study)
- Humbert M et al. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension." Eur Respir J 2023;61:2200879.
Discuss in detail about the various trials in the management of ANCA associated Vasculitis. From journals and rheumatology textbooks
Finding Sources
Finding Sources
Searching PubMed
"ANCA-associated vasculitis" AND "clinical trial"
Searching the Web
ANCA associated vasculitis clinical trials 2024 2025 avacopan rituximab maintenance treatment guidelines
Finding Sources
Finding Sources
Searching PubMed
"ANCA vasculitis" AND "maintenance" AND "rituximab"
Searching PubMed
"ANCA vasculitis" AND "plasma exchange" AND "cyclophosphamide"
Reading File
Reading File
Reading File
Reading Article
Reading Article
Finding Sources
Reading File
Reading File
Searching PubMed
"PEXIVAS" AND "plasma exchange" AND vasculitis
Reading File
Finding Sources
Reading Article
Reading Article
Reading File
Finding Sources
Finding Sources
Searching PubMed
"MAINRITSAN" OR "RITAZAREM" AND "ANCA vasculitis" AND rituximab maintenance
Reading File
Reading File
Reading File
Reading Web Page
ANCA vasculitis treatment trials recommendations 2025
Reading File
Reading File
Searching PubMed
"ANCA vasculitis" AND "mepolizumab" AND eosinophilic granulomatosis
Here are your comprehensive notes on clinical trials in the management of ANCA-associated vasculitis, compiled from rheumatology and nephrology textbooks plus the major trial literature.
Clinical Trials in the Management of ANCA-Associated Vasculitis
Sources: Firestein & Kelley's Textbook of Rheumatology (2022), Comprehensive Clinical Nephrology 7th Ed., Brenner & Rector's The Kidney, NKF Primer 8th Ed., Goldman-Cecil Medicine (2022), Harrison's Principles 22nd Ed. (2025); supplemented by major trial publications and 2025 BSR / 2022 KDIGO / 2022 EULAR guidelines.
1. Background and Treatment Framework
AAV encompasses GPA (Granulomatosis with Polyangiitis), MPA (Microscopic Polyangiitis), and EGPA (Eosinophilic Granulomatosis with Polyangiitis). Before immunosuppressive therapy, most patients died within 1 year. With treatment, 5-year patient survival reaches 65-75%, though adverse events from therapy remain a leading cause of death in the first year.
Treatment follows a three-phase strategy:
- Induction of remission (intensive phase, 3-6 months)
- Maintenance of remission (2-4 years)
- Treatment of relapse
The major clinical questions addressed by trials:
- Which immunosuppressant and route for induction (CYC vs. RTX; oral vs. IV CYC)?
- What is the role of plasma exchange?
- How much glucocorticoid is necessary?
- Which agent for maintenance and for how long?
- Can glucocorticoids be replaced (avacopan)?
- Disease-specific agents for EGPA?
Remission is induced in 75-90% of patients, but relapse is common (25-50%), demanding robust maintenance strategies.
2. Induction Trials
CYCLOPS Trial - IV vs. Oral Cyclophosphamide
| Parameter | Detail |
|---|---|
| Study | CYCLOPS (de Groot et al., ARD 2009) - European Vasculitis Study Group |
| Design | Multicenter RCT |
| Population | 149 newly diagnosed GPA/MPA, GFR >15 mL/min |
| Intervention | IV pulse CYC (0.35-0.5 g/m² every 2-3 weeks) vs. oral CYC 2 mg/kg/day, both × 3-6 months + GC |
| Primary endpoint | Time to remission |
| Result | Comparable remission rates; IV pulse: significantly lower cumulative CYC dose (8.2 g vs. 15.9 g); leukopenia less common (35% vs. 51%) |
| Long-term | Higher relapse rate observed with IV CYC at 18-month follow-up |
| Conclusion | IV pulse CYC is preferred for reducing cumulative dose/toxicity; oral CYC may offer marginally lower relapse rates in some settings |
- Comprehensive Clinical Nephrology 7th Ed.: "IV cyclophosphamide has similar remission rates as oral cyclophosphamide while reducing the total cyclophosphamide dose."
NORAM Trial - Methotrexate vs. Cyclophosphamide in Limited Disease
| Parameter | Detail |
|---|---|
| Study | NORAM (de Groot et al., ARD 2005) |
| Design | RCT, European Vasculitis Study Group |
| Population | Early limited GPA/MPA without severe organ involvement; creatinine <150 µmol/L |
| Intervention | MTX (15 mg/wk escalating to 25 mg/wk) vs. oral CYC 2 mg/kg/day × 12 months |
| Result | MTX remission comparable to CYC at 6 months (89.8% vs. 93.5%, NS); but slower onset, especially with pulmonary disease |
| Relapse rate | MTX: 69.5% vs. CYC: 46.5% - significantly higher |
| Conclusion | MTX acceptable for non-severe, non-renal AAV; NOT for renal disease; higher relapse rate limits use |
RAVE Trial - Rituximab vs. Cyclophosphamide (Induction) - Landmark
| Parameter | Detail |
|---|---|
| Study | RAVE (Stone et al., NEJM 2010) |
| Design | Phase III, randomized, double-blind, double-dummy, noninferiority RCT |
| Population | 197 patients with GPA (75%) or MPA (24%), newly diagnosed AND relapsing |
| Intervention | RTX 375 mg/m² IV × 4 weekly doses vs. oral CYC 2 mg/kg/day (×3 months then AZA); both with GC taper |
| Primary endpoint | Complete remission (BVAS/WG = 0 + completed prednisone taper) at 6 months |
| Overall result | RTX 64% vs. CYC 55% (p = 0.21); noninferiority met (p < 0.001) |
| Relapsing disease subgroup | RTX superior: 67% vs. 42% remission (p = 0.01) |
| PR3-ANCA subgroup | RTX trend toward superiority |
| 18-month extension | Specks et al., NEJM 2013: sustained benefit maintained; RTX still superior for relapsing disease |
| Adverse events | Similar between groups |
| Conclusion | RTX non-inferior to CYC for induction overall; superior for relapsing disease and PR3-ANCA patients; established RTX as first-line alongside CYC |
- Rheumatology 2022 Elsevier: "Subgroup analysis showed that RTX was more efficacious than cyclophosphamide in patients with relapsing disease at baseline."
RITUXVAS Trial - Rituximab vs. Cyclophosphamide in Renal AAV
| Parameter | Detail |
|---|---|
| Study | RITUXVAS (Jones et al., NEJM 2010) |
| Design | RCT, European Vasculitis Study Group |
| Population | 44 patients with new-onset ANCA-associated renal vasculitis; GFR <45 mL/min (or dialysis-dependent) |
| Intervention | RTX 375 mg/m² × 4 + 2 IV CYC pulses (days 1 and 15) vs. IV CYC × 3-6 months + AZA; both with GC |
| Primary endpoint | Sustained remission at 12 months |
| Result | RTX group 76% vs. control 82% sustained remission (p = 0.68) - no significant difference |
| Adverse events | Similar early severe AEs |
| Conclusion | RTX comparable to IV CYC for severe renal AAV; validated FDA/EMA approval for renal disease |
RAVE vs. RITUXVAS - Key Differences:
| Feature | RAVE | RITUXVAS |
|---|---|---|
| RTX dose | 375 mg/m² × 4 alone | 375 mg/m² × 4 + 2 CYC pulses |
| Comparator | Oral CYC then AZA | IV CYC then AZA |
| Population | New + relapsing | New onset, severe renal only |
| Primary outcome | Non-inferior | Non-inferior |
| Relapse benefit | Yes (for relapsing disease) | Not powered |
WGET Trial - Etanercept (TNF Inhibitor) in GPA
| Parameter | Detail |
|---|---|
| Study | WGET (Stone et al., NEJM 2003) |
| Design | RCT (n = 180) |
| Intervention | Etanercept added to standard therapy vs. standard therapy alone |
| Result | No benefit in remission or relapse reduction; 6 solid tumors in etanercept arm vs. 0 in placebo |
| Conclusion | TNF inhibitors are contraindicated in GPA/AAV - increased malignancy risk |
3. Plasma Exchange Trials
MEPEX Trial - Plasma Exchange vs. IV Methylprednisolone
| Parameter | Detail |
|---|---|
| Study | MEPEX (Jayne et al., JASN 2007) |
| Design | RCT, European Vasculitis Study Group |
| Population | 137 patients with severe ANCA-associated GN; serum creatinine >5.8 mg/dL (dialysis-risk) |
| Intervention | Plasma exchange (7 sessions over 14 days) vs. IV methylprednisolone 3 g; both with oral CYC + GC |
| Primary endpoint | Renal recovery (dialysis independence) at 3 months |
| Result | PE: 69% renal recovery vs. pulse MP: 49% (p = 0.02) - PE significantly superior for early renal recovery |
| 5-year follow-up | No significant difference in ESKD-free survival (45% vs. 43%); limited by sample size |
| Conclusion | PE improves early renal recovery in dialysis-dependent AAV; long-term benefit unproven - led directly to PEXIVAS |
PEXIVAS Trial - Practice-Changing Study on Plasma Exchange and GC Dosing
| Parameter | Detail |
|---|---|
| Study | PEXIVAS (Walsh et al., NEJM 2020; Jayne et al. full report PMID: 36155131) |
| Design | International (95 centres, Europe/North America/Australia/Japan), open-label, 2×2 factorial RCT |
| Population | 704 patients with GPA or MPA; GFR <50 mL/min/1.73 m² OR diffuse alveolar haemorrhage (DAH) |
| Arms | (1) PE × 7 sessions within 14 days vs. no PE; AND (2) standard-dose GC vs. reduced-dose GC (60% less cumulative oral GC by month 6) |
| Primary outcome | Composite all-cause mortality + ESKD |
| PE result | Primary endpoint: PE 28% vs. no PE 31% (HR 0.86; 95% CI 0.65-1.13; p = 0.3) - NO BENEFIT |
| Reduced GC result | Non-inferiority met (risk difference 2.3%, p = 0.5); serious infections: IRR 0.69 (0.52-0.93) - significantly fewer |
| DAH subgroup (2024) | Fussner et al., AJRCCM 2024 [PMID: 38346237]: PE not beneficial even in DAH subgroup |
| Early kidney function (2025) | Odler et al., Kidney Int 2025 [PMID: 39708998]: PE improved early kidney recovery only transiently |
| Conclusion | Plasma exchange no longer routinely recommended in AAV - even for severe renal disease or DAH. Reduced-dose GC is the new standard (same efficacy, fewer infections) |
- Firestein & Kelley's: "The reduced-dose regimen met its noninferiority endpoint for the efficacy outcome of death or end-stage renal disease, and patients in the lower-dose group had fewer infections (IRR 0.69; CI 0.52–0.93)."
- 2025 BSR: "Adjunctive plasmapheresis is not routinely recommended for pulmonary haemorrhage without severe kidney involvement."
4. Glucocorticoid Reduction Trials
PEXIVAS Reduced-Dose GC Arm (see above)
Reduced-dose GC regimen achieves ~50% less cumulative oral GC in the first 6 months vs. standard, tapering to 5 mg/day by month 4-5 (PEXIVAS schedule). Non-inferior outcome, significantly fewer infections. This is now the recommended GC-reduction protocol for organ-threatening AAV.
LOVAS Trial - Low-Dose GC in Non-Severe AAV
| Parameter | Detail |
|---|---|
| Study | LOVAS (Furuta et al., ARD 2021) |
| Design | RCT; Japan |
| Population | 140 patients with non-severe (non-organ-threatening) AAV |
| Intervention | Standard prednisolone (1 mg/kg/day) vs. reduced prednisolone (0.5 mg/kg/day) |
| Primary endpoint | Remission at 6 months |
| Result | Reduced dose 71.0% vs. standard 69.2% - noninferiority met |
| Adverse events | Serious AEs: 18.8% vs. 36.9% (p = 0.02); serious infections: 7.2% vs. 20.0% (p = 0.04) |
| Conclusion | Reduced GC (0.5 mg/kg, LoVAS schedule) for non-severe AAV - same efficacy, fewer AEs |
- Firestein & Kelley's: "Thus it is probable that standard glucocorticoid schedules developed over the past 50 years have used unnecessarily high doses."
5. The ADVOCATE Trial - Avacopan as Glucocorticoid Replacement
Scientific Basis
Complement activation is central to AAV pathogenesis. ANCA-activated neutrophils generate C5a, which recruits and primes further neutrophils in a positive feedback loop. Avacopan is an oral, selective C5a receptor 1 (C5aR1/CD88) inhibitor - blocking this amplification loop without abolishing total complement function.
Phase II - CLEAR Trial (Jayne et al., JASN 2017)
67 patients; avacopan ± low-dose prednisone showed comparable efficacy to high-dose prednisone for remission induction. Supported phase III development.
Phase III - ADVOCATE Trial (Jayne et al., NEJM 2021) - Landmark
| Parameter | Detail |
|---|---|
| Design | Phase III, double-blind, double-dummy, active-controlled, multinational RCT |
| Population | 331 patients with newly diagnosed or relapsing GPA or MPA |
| Intervention | Avacopan 30 mg BD × 52 weeks (replacing prednisone taper) vs. Standard prednisone taper (45-60 mg/day, tapering over 26 weeks); both groups received background RTX or CYC per physician choice |
| Primary endpoint 1 | Remission at week 26 (BVAS = 0) |
| Primary endpoint 2 | Sustained remission at week 52 |
| Week 26 result | Avacopan 72.3% vs. prednisone 70.1% (noninferiority: p < 0.0001) |
| Week 52 result | Avacopan 65.7% vs. prednisone 54.9% (superiority: p = 0.007) |
| GFR improvement | Avacopan +7.3 vs. prednisone +4.1 mL/min/1.73 m² - significant renal benefit |
| GC toxicity | Glucocorticoid Toxicity Index significantly lower with avacopan (Patel et al., Lancet Rheumatol 2023 [PMID: 38251609]) |
| Quality of Life | Significant HRQoL improvements favouring avacopan (Strand et al., Lancet Rheumatol 2023 [PMID: 38251577]): SF-36 physical component, EQ-5D health utilities |
| Adverse events | Serious AEs: avacopan 42.4% vs. prednisone 45.5% (similar); liver enzyme elevations: 11% vs. 8% |
| Regulatory approval | FDA: October 2021; EMA: January 2022 |
Post-hoc ADVOCATE sub-analyses (2024-2025):
-
Elderly patients (≥65 years): Avacopan effective and well-tolerated (Geetha et al. Rheumatology 2025 [PMID: 40037556])
-
CYC background: Avacopan effective with both RTX and CYC (Geetha et al. RMD Open 2025 [PMID: 41052893])
-
Low GFR (<20 mL/min): Greater renal recovery benefit in most severely impaired patients
-
Respiratory disease: Effective in patients with respiratory tract AAV manifestations (Specks et al., ACR Open Rheumatol 2025)
-
2025 BSR Guidelines: Avacopan is now a recommended replacement for the prednisone taper as part of induction therapy for GPA/MPA (GRADE 1A).
-
2022 EULAR: Avacopan recommended as part of induction regimen for GPA/MPA.
6. Maintenance Trials
CYCAZAREM - Azathioprine vs. Cyclophosphamide for Maintenance
| Parameter | Detail |
|---|---|
| Study | CYCAZAREM (Jayne et al., NEJM 2003) |
| Design | RCT, European Vasculitis Study Group (n = 144) |
| Population | GPA/MPA in remission after CYC + GC induction |
| Intervention | Continue oral CYC 1.5 mg/kg/day vs. switch to AZA 2 mg/kg/day at 3 months of remission |
| Result | Relapse at 18 months: CYC 15.5% vs. AZA 13.7% (p = NS); adverse events similar |
| Conclusion | AZA equivalent to CYC for maintenance - CYC not required beyond remission induction; AZA established as standard maintenance |
WEGENT - Azathioprine vs. Methotrexate for Maintenance
| Parameter | Detail |
|---|---|
| Study | WEGENT (French Vasculitis Study Group) |
| Design | RCT |
| Intervention | AZA 2 mg/kg/day vs. MTX 0.3 mg/kg/wk (max 25 mg) for maintenance |
| Result | No significant difference in relapse rate or toxicity between AZA and MTX |
| Conclusion | MTX as effective as AZA for maintenance; avoid in GFR <30 mL/min |
IMPROVE - Mycophenolate Mofetil vs. Azathioprine
| Parameter | Detail |
|---|---|
| Study | IMPROVE (Hiemstra et al., ARD 2010) |
| Design | RCT, European Vasculitis Study Group |
| Intervention | MMF 2 g/day vs. AZA 2 mg/kg/day |
| Result | MMF significantly inferior: higher relapse rate (HR 1.69; 95% CI 1.06-2.70) |
| Cancers | AZA arm: 2 bladder + 3 skin cancers; MMF arm: 1 skin cancer |
| Conclusion | MMF inferior to AZA for maintenance - not recommended as first-line; 2025 BSR recommends MMF only if RTX/AZA/MTX contraindicated/not tolerated |
MAINRITSAN 1 - Rituximab vs. Azathioprine Maintenance - Landmark
| Parameter | Detail |
|---|---|
| Study | MAINRITSAN (Guillevin et al., NEJM 2014) |
| Design | RCT, French Vasculitis Study Group |
| Population | 115 patients with GPA, MPA, or renal-limited vasculitis in complete remission after CYC induction |
| Intervention | RTX 500 mg IV at day 0, day 14, then every 6 months × 18 months vs. AZA 2 mg/kg/day (tapered over 22 months) |
| Primary endpoint | Major relapse rate at 28 months |
| Result | Major relapses: RTX 5% vs. AZA 29% (p < 0.001) |
| 60-month follow-up | Severe relapses off treatment: RTX 28.1% vs. AZA 50.6% (HR 2.51 for AZA, p = 0.003) - benefit persists but accelerates after stopping |
| Adverse events | Similar severe infections, malignancy |
| Conclusion | RTX greatly superior to AZA for maintenance; established RTX as preferred maintenance agent for AAV |
MAINRITSAN 2 - Fixed vs. Tailored Rituximab Dosing
| Parameter | Detail |
|---|---|
| Study | MAINRITSAN 2 (Terrier et al., Ann Intern Med 2021) |
| Design | RCT (n = 162) |
| Population | GPA/MPA in complete remission after CYC induction |
| Intervention | Fixed schedule: RTX 500 mg every 6 months vs. Tailored: RTX 500 mg upon CD19+ B-cell reappearance OR ANCA titer doubling |
| Result | Major relapse at 28 months: fixed 9.9% vs. tailored 17.3% (p = 0.22) - not significantly different |
| Infusions | Fixed: median 5; tailored: median 3 - fewer infusions with tailored |
| Conclusion | Tailored dosing non-inferior; reduces drug burden and infusion frequency |
MAINRITSAN 3 - Extended RTX vs. Placebo (Post-Maintenance Extension)
| Parameter | Detail |
|---|---|
| Study | MAINRITSAN 3 (Terrier et al., ARD 2021) |
| Design | RCT placebo-controlled extension |
| Population | Patients completing MAINRITSAN 2 |
| Intervention | Continue RTX 500 mg biannually vs. placebo |
| Result | Major relapse-free survival: RTX 100% vs. placebo 87% (p = 0.009) |
| Adverse events | Similar |
| Conclusion | Extended maintenance beyond 2 years reduces relapse; supports longer-term RTX therapy |
RITAZAREM - Rituximab vs. Azathioprine in Relapsing AAV
| Parameter | Detail |
|---|---|
| Study | RITAZAREM (Smith et al., ARD 2019) |
| Design | RCT (n = 170) |
| Population | Relapsing ANCA vasculitis in remission after RTX induction (1 g × 2 doses) - key difference from MAINRITSAN 1 |
| Intervention | RTX 1000 mg IV every 4 months × 5 doses (more frequent/higher dose than MAINRITSAN) vs. AZA 2 mg/kg/day |
| Primary endpoint | Relapse rate at 24 months |
| Result | During treatment: relapses 13/85 (RTX) vs. 32/85 (AZA); HR 0.35 (0.18-0.66) |
| Severe relapses | 6 (RTX) vs. 17 (AZA) |
| Serious AEs | RTX 22% vs. AZA 36% during treatment period |
| 36-month (off treatment) | Benefit sustained: HR 0.41 (0.27-0.61) |
| Conclusion | RTX markedly superior to AZA for relapsing AAV; higher RTX dose (1000 mg/4 months) supports use in higher-risk patients |
- Firestein & Kelley's: "Fewer relapses were seen in the rituximab group (HR, 0.35; 96% CI, 0.18–0.66). Including a follow-up period off treatment (to 36 months since enrollment), fewer relapses were still seen in the rituximab group (HR, 0.41; 95% CI, 0.27–0.61)."
B-Cell-Guided vs. ANCA-Guided RTX Maintenance (Zonozi et al. 2024)
| Parameter | Detail |
|---|---|
| Study | Zonozi R et al., Ann Rheum Dis 2024 [PMID: 38123922] |
| Design | Prospective, single-centre, open-label RCT (n = 115) |
| Population | ANCA vasculitis in remission after ≥2 years of fixed-schedule RTX |
| Intervention | B-cell arm: RTX upon CD19+ B-cell repopulation vs. ANCA arm: RTX upon significant ANCA rise |
| Primary endpoint | Clinical relapse (modified BVAS/WG >0) by 36 months |
| Result | Relapse at 3 years: B-cell arm 4.1% vs. ANCA arm 20.5% (p = 0.045) |
| Safety | Total SAEs and deaths equivalent; COVID-19 SAEs higher in B-cell arm |
| RTX exposure | B-cell arm: 3.6 infusions vs. ANCA arm: 0.5 infusions per patient |
| Conclusion | B-cell-guided dosing is superior to ANCA-guided for preventing relapse; preferred long-term maintenance strategy |
Duration Comparison - Karras et al. (AZA 24 vs. 48 Months)
AZA × 48 months had fewer relapses (22% vs. 63%) but more serious AEs (9 vs. 3 events) than × 24 months. Current guidelines recommend 24-48 months of maintenance, with individual risk assessment guiding duration.
7. TMP-SMX as Adjunct Maintenance
Stegeman et al. RCT (NEJM 1996)
| Parameter | Detail |
|---|---|
| Population | GPA patients in remission |
| Intervention | TMP-SMX 960 mg BD vs. placebo |
| Result | TMP-SMX reduced relapses (23% vs. 40%; p = 0.02) and infections - especially upper respiratory |
| Mechanism | Eliminates nasal Staphylococcus aureus colonization - major relapse trigger in GPA |
| Conclusion | TMP-SMX recommended as adjunct in GPA with nasal/sinus involvement; not a substitute for standard immunosuppression; also provides Pneumocystis jirovecii prophylaxis |
8. Trials in EGPA
Five Factor Score (FFS) - Risk Stratification Framework
The French Vasculitis Study Group developed the FFS to guide treatment intensity in EGPA. Poor prognostic factors (original FFS):
- Serum creatinine >1.58 mg/dL
- Proteinuria >1 g/day
- Severe GI involvement
- Cardiomyopathy
- CNS involvement
FFS = 0: GC alone sufficient; FFS ≥1: Add CYC. Approximately 35% of FFS=0 patients relapse on GC taper alone.
MIRRA Trial - Mepolizumab in EGPA - Landmark
| Parameter | Detail |
|---|---|
| Study | MIRRA (Wechsler et al., NEJM 2017) |
| Design | Phase III, double-blind, placebo-controlled RCT (n = 136) |
| Population | Relapsing or refractory EGPA on oral GC ≥7.5 mg/day |
| Intervention | Mepolizumab 300 mg SC every 4 weeks × 52 weeks vs. placebo; both with standard of care |
| Primary endpoints | (1) Accrued weeks of remission (BVAS = 0, prednisolone ≤4 mg/day); (2) Proportion in remission at weeks 36 and 48 combined |
| Remission rate | Mepolizumab: 28% vs. placebo: 3% in remission at weeks 36 and 48 (OR 5.91; p < 0.001) |
| Accrued remission | Significantly superior (26% vs. 8% of study weeks in full remission) |
| Steroid sparing | Daily prednisolone at 48 weeks: 4.0 mg (mepolizumab) vs. 10.0 mg (placebo) |
| Relapse | Lower relapse rate; eosinophil counts normalized |
| Adverse events | Similar; nasopharyngitis most common |
| Mechanism | Anti-IL-5 monoclonal antibody - reduces eosinophil survival and differentiation |
| Approval | FDA: December 2017; EMA: September 2018 - first targeted biologic for EGPA |
| Conclusion | Mepolizumab is the standard biologic therapy for relapsing/refractory EGPA; significant steroid-sparing |
Rituximab for EGPA - Phase III Trial (Terrier et al. 2025)
| Parameter | Detail |
|---|---|
| Study | Terrier B et al., Ann Intern Med 2025 [PMID: 40720835] |
| Design | Phase III, multicenter, double-blind, randomized, superiority RCT; France (n = 105) |
| Population | Newly diagnosed or relapsing EGPA (BVAS ≥3) |
| Intervention | RTX 1 g × 2 doses (2 weeks apart) + GC vs. conventional strategy (GC alone or GC + CYC for severe forms) |
| Primary endpoint | Remission (BVAS = 0 + prednisolone ≤7.5 mg/day) at day 180 |
| Result | RTX 63.5% vs. control 60.4% (RR 1.05; 95% CI 0.78-1.42; p = 0.75) - not superior |
| Duration of remission | RTX 48.5 weeks vs. control 49.1 weeks (p = 0.41) |
| Adverse events | No significant differences |
| Conclusion | RTX not superior to conventional therapy for EGPA; unlike GPA/MPA, RTX is not first-line; ANCA-positive EGPA patients may benefit more (post-hoc observation) |
Azathioprine vs. CYC for EGPA Maintenance
An earlier RCT (Guillevin et al.) confirmed AZA comparable to continued CYC for EGPA maintenance - similar to findings in GPA/MPA.
9. Emerging Trials (2022-2026)
ALEVIATE - Alemtuzumab in Refractory AAV
| Parameter | Detail |
|---|---|
| Study | ALEVIATE (Gopaluni et al., Arthritis Res Ther 2022 [PMID: 35365179]) |
| Design | Randomized, dose-ranging, phase II/III trial |
| Population | Refractory primary systemic vasculitis including AAV |
| Intervention | Alemtuzumab (anti-CD52 monoclonal antibody) at different doses |
| Result | Dose-dependent efficacy in refractory disease; significant infectious complications and secondary autoimmune events |
| Conclusion | Alemtuzumab may rescue refractory disease; significant toxicity profile; not standard care |
IFX-1 - Anti-C5a Monoclonal Antibody
Unlike avacopan (which blocks the C5aR1 receptor), IFX-1 neutralizes the C5a ligand directly. Phase II trials ongoing (NCT03712345, NCT03895801). Results awaited.
Novel Anti-CD20 Agents
Obinutuzumab, ocrelizumab, ofatumumab - fully humanized anti-CD20 antibodies being evaluated to avoid RTX immunogenicity and serum sickness. Early phase data only; no AAV-specific RCTs yet.
Long-Term Avacopan Duration Trial (NCT06072482, Ongoing)
A 5-year RCT comparing avacopan × 5 years vs. × 1 year vs. placebo on top of SoC to determine optimal duration of C5aR inhibition.
10. Summary Table of Major Trials
| Trial | Year | Design | Question | Key Result | Conclusion |
|---|---|---|---|---|---|
| CYCLOPS | 2009 | RCT | IV vs. oral CYC induction | Equal remission; IV = lower CYC dose | IV pulse CYC preferred |
| NORAM | 2005 | RCT | MTX vs. CYC (limited GPA) | MTX comparable at 6m; higher relapse rate | MTX only for limited non-renal disease |
| RAVE | 2010 | Phase III RCT | RTX vs. oral CYC induction | Non-inferior; RTX superior in relapsing | RTX = CYC; RTX preferred for relapsing/PR3 |
| RITUXVAS | 2010 | RCT | RTX+2CYC vs. CYC (renal AAV) | No difference at 12m | RTX comparable to CYC in severe renal |
| WGET | 2003 | RCT | Etanercept in GPA | No benefit; increased solid tumors | TNF inhibitors contraindicated in AAV |
| MEPEX | 2007 | RCT | PE vs. IV MP (severe renal) | PE better early renal recovery | PE for dialysis-dependent; long-term unclear |
| PEXIVAS | 2020 | Factorial RCT (n=704) | PE vs. no PE; reduced vs. standard GC | PE: no benefit; reduced GC: non-inferior + fewer infections | PE not recommended; use reduced GC |
| LOVAS | 2021 | RCT | Reduced vs. standard GC (non-severe) | Non-inferior; fewer AEs with reduced dose | Reduced GC (0.5 mg/kg) for non-severe AAV |
| Stegeman | 1996 | RCT | TMP-SMX adjunct in GPA remission | Fewer relapses; fewer infections | TMP-SMX adjunct for upper tract GPA |
| CYCAZAREM | 2003 | RCT | AZA vs. CYC maintenance | Equivalent relapse/toxicity | AZA replaces CYC after remission |
| WEGENT | 2008 | RCT | AZA vs. MTX maintenance | Equivalent | AZA or MTX for maintenance |
| IMPROVE | 2010 | RCT | MMF vs. AZA maintenance | MMF inferior (higher relapse) | AZA preferred over MMF |
| MAINRITSAN 1 | 2014 | RCT | RTX vs. AZA maintenance | RTX: 5% vs. AZA: 29% major relapse | RTX is preferred maintenance agent |
| MAINRITSAN 2 | 2021 | RCT | Fixed vs. tailored RTX | No significant difference; tailored = fewer infusions | Tailored dosing acceptable |
| MAINRITSAN 3 | 2021 | RCT | Extended RTX vs. placebo | RTX: 100% vs. placebo: 87% relapse-free survival | Extended maintenance beneficial |
| RITAZAREM | 2019 | RCT | RTX vs. AZA (relapsing AAV) | HR 0.35 favoring RTX | RTX markedly superior in relapsing disease |
| B-cell vs ANCA-guided (Zonozi 2024) | 2024 | RCT | B-cell vs. ANCA-triggered RTX | B-cell: 4.1% vs. ANCA: 20.5% relapse | B-cell guided dosing preferred |
| ADVOCATE | 2021 | Phase III RCT | Avacopan vs. prednisone taper | Superior at W52; better QoL/renal function | Avacopan replaces prednisone taper |
| MIRRA | 2017 | Phase III RCT | Mepolizumab vs. placebo (EGPA) | 28% vs. 3% remission; major steroid-sparing | Mepolizumab first-line for relapsing EGPA |
| RTX for EGPA (Terrier 2025) | 2025 | Phase III RCT | RTX vs. conventional (EGPA) | Not superior | RTX not first-line in EGPA |
| ALEVIATE | 2022 | Phase II/III RCT | Alemtuzumab in refractory AAV | Efficacy but significant toxicity | Reserved for refractory disease |
11. Current Guideline Recommendations (2025 BSR / 2022 KDIGO / 2022 EULAR)
Induction of Remission (GPA/MPA)
- IV pulsed CYC or RTX + GC for all active GPA/MPA (GRADE 1A)
- RTX preferred for relapsing disease (GRADE 1B)
- CYC + RTX combination may be considered for life/organ-threatening disease
- GC: PEXIVAS reduced-dose regimen (target 5 mg/day by month 4-5); IV methylprednisolone pulses NOT routinely recommended
- Avacopan (30 mg BD × 52 weeks) replaces prednisone taper as part of induction (GRADE 1A, BSR 2025)
Maintenance of Remission (GPA/MPA)
- RTX 500-1000 mg every 4-6 months preferred (GRADE 1)
- B-cell-guided dosing preferred over ANCA-guided dosing
- Alternatives: AZA 2 mg/kg/day or MTX 0.25-0.3 mg/kg/wk
- MMF only if RTX/AZA/MTX not tolerated
- Duration: 24-48 months (risk-stratified)
EGPA
- GC alone for FFS = 0; CYC + GC for FFS ≥1
- Mepolizumab (300 mg SC every 4 weeks) for relapsing/refractory EGPA
- RTX not first-line in EGPA (negative phase III RCT, 2025)
Key References
Textbooks:
- Firestein & Kelley's Textbook of Rheumatology (2022), Chapters 86-87
- Comprehensive Clinical Nephrology 7th Ed., Chapter 26
- Brenner & Rector's The Kidney (2-Vol), Chapters 18-19
- NKF Primer on Kidney Diseases 8th Ed., Chapter 2
- Goldman-Cecil Medicine (2022), Chapter 69
- Harrison's Principles of Internal Medicine 22nd Ed. (2025), Chapter 375
Major Trial Publications:
- Stone JH et al. (RAVE). NEJM 2010;363:221-232
- Jones RB et al. (RITUXVAS). NEJM 2010;363:211-220
- Walsh M et al. (PEXIVAS). NEJM 2020;382:622-631 [Full report: PMID 36155131]
- Jayne DRW et al. (ADVOCATE). NEJM 2021;384:599-609
- Guillevin L et al. (MAINRITSAN). NEJM 2014;371:1771-1780
- Terrier B et al. (MAINRITSAN 2). Ann Intern Med 2021
- Terrier B et al. (MAINRITSAN 3). ARD 2021
- Smith RM et al. (RITAZAREM). ARD 2019
- Wechsler ME et al. (MIRRA). NEJM 2017;377:1521-1531
- Zonozi R et al. Ann Rheum Dis 2024 [PMID: 38123922]
- Terrier B et al. (RTX in EGPA). Ann Intern Med 2025 [PMID: 40720835]
- Fussner LA et al. (PEXIVAS-DAH). AJRCCM 2024 [PMID: 38346237]
- Patel NJ et al. (ADVOCATE-GTI). Lancet Rheumatol 2023 [PMID: 38251609]
- Strand V et al. (ADVOCATE-QoL). Lancet Rheumatol 2023 [PMID: 38251577]
- Geetha D et al. (ADVOCATE elderly). Rheumatology 2025 [PMID: 40037556]
Generate a PowerPoint presentation summarizing all major AAV trials and current treatment algorithms
Reading File
Reading File
Reading File
Running Command
Running Command
Continue
Generate a PowerPoint presentation summarizing all major AAV trials and current treatment algorithms
Reading File
Reading File
This is a shared conversation. Sign in to Orris to start your own chat.